Citation:Rubenstein JH, Vakil N, Inadomi JM 2005

From Clinical Guidelines Wiki


Rubenstein JH, Vakil N, Inadomi JM. The cost-effectiveness of biomarkers for predicting the development of oesophageal adenocarcinoma. Aliment Pharmacol Ther 2005 Jul 15;22(2):135-46 Abstract available at

Critical appraisals

Critical appraisal linkClinical questionAssigned toStatus
Are there useful biomarkers to detect and improve the diagnosis of neoplasia in patients with or without BO?Melissa Thomaspending

Compare quality appraisals for each clinical question

Cited by

  1. Is surveillance cost-effective for follow-up of patients with BO?